Bormioli Pharma has completed its acquisition of Remy & Geiser (R&G), a German company active in the business of plastic and glass primary packaging mainly used in the pharmaceutical industry.
The acquisition is a significant step on the growth path that Bormioli Pharma has undertaken since December 2017, when it became an independent company owned by Triton Investment Fund.
R&G develops, manufactures and sales closure, dosing systems, pipette droppers and tubular glass vials. The Italian company employs approximately 270 people and operates through 2 plants located in Germany (Schleusingen and Altenfeld).
"This acquisition is part of a wider development plan aimed to make of Bormioli Pharma a truly global and innovative player," said Andrea Lodetti, Bormioli Pharma's CEO. "Through this operation Bormioli Pharma reinforces its presence in the German and Northern European markets [and] expands its current offering with complementary products and strengthens its manufacturing footprint adding more technological capabilities".
"We are proud to become a part of a solid and international group like Bormioli Pharma," said Dr Friedrich Hillebrand, Remy & Geiser's owner. "With this step Remy & Geiser achieves further development potential and broadens its future horizons. It is a project I strongly believe in, and I am honoured to join the Group as Member of the Board of Directors".
